BrightSpring Health Services, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance

Why It Matters

The results underscore BrightSpring’s accelerating growth in home‑based care, improving profitability and financial flexibility, which strengthens its position in a rapidly expanding healthcare market.

Key Takeaways

• Revenue up 28% YoY, reaching $12.9B.
• Net income flips to $104.8M after prior loss.
• Adjusted EBITDA rises 34% to $618M.
• Leverage improves to 2.99× from 4.16×.
• 2026 guidance targets up to $15B revenue, $790M EBITDA.

Pulse Analysis

BrightSpring’s 2025 performance reflects broader industry momentum as demand for home‑based and community‑based health services surges amid an aging population and a shift toward value‑based care. By expanding its pharmacy solutions and provider services, the company captured double‑digit revenue growth, while strategic acquisitions such as Amedisys and LHC added over 100 new branches, enhancing geographic reach and service depth. This scaling aligns with investors’ appetite for scalable, high‑margin health‑tech platforms that can deliver cost‑effective care outside traditional hospital settings.

The financial metrics reveal a decisive turnaround: operating cash flow jumped to $490 million, and leverage fell to 2.99×, indicating stronger balance‑sheet health. Share repurchases signal confidence in cash generation and a commitment to returning value to shareholders. Adjusted EBITDA growth outpaced revenue, suggesting operational efficiencies and effective integration of recent acquisitions. For analysts, the combination of profit acceleration, disciplined capital allocation, and a solid cash position positions BrightSpring as a compelling growth story within the fragmented home‑health sector.

Looking ahead, BrightSpring’s 2026 guidance anticipates continued double‑digit top‑line expansion and a near‑30% rise in adjusted EBITDA, driven by the integration of the Amedisys/LHC assets and a focused push on its provider segment, which is projected to grow up to 29.7%. The pending divestiture of the Community Living business will streamline the portfolio, allowing management to concentrate on higher‑margin, integrated care solutions. While regulatory changes and reimbursement pressures remain risks, the company’s diversified service lines and robust pipeline suggest it is well‑positioned to capitalize on the evolving landscape of coordinated, lower‑cost patient care.